财务报表上一路攀升的负债率数字，逼迫着这家曾以“三无”身份登陆科创板的 创新药 企，再次走上寻求资本输血的征途。12月19日，苏州泽璟生物制药股份有限公司正式向香港联交所递交H股上市申请。若此次发行成功，这家在科创板上市近六年的生物制药企业将完成“A+H”资本布局。六年上市路六年前， 泽璟制药 以“无产品、无收入、无利润”的“三无”身份登陆科创板，成为A股市场的一个特殊案例。如今公司已拥有三款...
Source Link财务报表上一路攀升的负债率数字，逼迫着这家曾以“三无”身份登陆科创板的 创新药 企，再次走上寻求资本输血的征途。12月19日，苏州泽璟生物制药股份有限公司正式向香港联交所递交H股上市申请。若此次发行成功，这家在科创板上市近六年的生物制药企业将完成“A+H”资本布局。六年上市路六年前， 泽璟制药 以“无产品、无收入、无利润”的“三无”身份登陆科创板，成为A股市场的一个特殊案例。如今公司已拥有三款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.